Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “PSNL.”

Personalis is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. Personalis’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Donald K. Lang and Benson Richards. Partner Rachel D. Kleinberg provided tax advice. Partner David R. Bauer, counsel Bonnie Chen and associate S. Dream Montgomery provided intellectual property and technology advice. Counsel Gregory D. Hughes provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post